Publications

miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study. Gagez AL, Duroux-Richard I, Leprêtre S, Orsini-Piocelle F, Letestu R, De Guibert S, Tuaillon E, Leblond V, Khalifa O, Gouilleux-Gruart V, Banos A, Tournilhac O, Dupuis J, Jorgensen C, Cartron G, Apparailly F. Haematologica. 2017 Apr;102(4):746-754.

Differential morphological and functional features of fibroblasts explanted from Solar Lentigo. Goorochurn R, Viennet C, Tissot M, Locatelli F, Granger C, Varin-Blank N, Humbert P, Le Roy C. Br J Dermatol. 2017 Feb 17.

Phosphorylation impact on Spleen Tyrosine kinase conformation by Surface Enhanced Raman Spectroscopy. Cottat M, Yasukuni R, Homma Y, Lidgi-Guigui N, Varin-Blank N, Lamy de la Chapelle M, Le Roy C. Sci Rep. 2017 Jan 5;7:39766.

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U,Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC. Blood. 2017 Apr 3.

Scleroderma peripheral B lymphocytes secrete interleukin-6 and TGF-β and activate fibroblasts. Dumoitier N, Chaigne B, Régent A, Lofek S, Mhibik M, Dorfmüller P, Terrier B, London J, Bérezné A, Tamas N, Varin-Blank N, Mouthon L. Arthritis Rheumatol. 2016 Dec 19.

Biological processes in solar lentigo: insights brought by experimental models. Goorochurn R, Viennet C, Granger C, Fanian F, Varin-Blank N, Le Roy C, Humbert P. Exp Dermatol. 2016 Mar;25(3):174-7.

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study. Meunier G, Ysebaert L, Nguyen-Thi PL, Lepretre S, Quinquenel A, Dupuis J, Lemal R, Aurran T, TomowiakC, Cymbalista F, Dilhuydy MS, Brion A, Morel P, Cazin B, Leblond V, Cartron G, Ré D, Béné MC, Michallet AS, Feugier P. Hematol Oncol. 2016 Nov 22.

Cellular response to alkylating agent MNNG is impaired in STAT1-deficients cells. Ah-Koon L, Lesage D, Lemadre E, Souissi I, Fagard R, Varin-Blank N, Fabre EE, Schischmanoff O. J Cell Mol Med. 2016 Oct;20(10):1956-65.

Aortic VCAM-1: an early marker of vascular inflammation in collagen-induced arthritis. Denys A, Clavel G, Lemeiter D, Schischmanoff O, Boissier MC, Semerano L. J Cell Mol Med. 2016 May;20(5):855-63.

Evaluation of paroxysmal nocturnal hemoglobinuria screening by flow cytometry through multicentric interlaboratory comparison in four countries. Debliquis A, Wagner-Ballon O, Le Garff-Tavernier M, Fossat C, Chatelain B, Letestu R, Drénou B; HPNAFCGroup. Am J Clin Pathol. 2015 Dec;144(6):858-68.

CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling. Arnaud MP, Vallée A, Robert G, Bonneau J, Le Roy C, Varin-Blank N, Rio AG, Troadec MB, Galibert MD, Gandemer V. Blood 2015 Oct 8;126(15):1802-12.

Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderlypatients with chronic lymphocytic leukemia. Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Leprêtre S, Dilhuydy MS, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, De Guibert S, Aurran T, Laribi K, Vilque JP, Tournilhac O, Delmer A,Feugier P, Cazin B, Michallet AS, Lévy V, Troussard X, Delepine R, Tavernier E, Colombat P, Leblond V. Leuk Lymphoma. 2015 Sep 28:1-7.

Mutation of Vav1 adaptor region reveals a new oncogenic activation. Razanadrakoto L, Cormier F, Laurienté V, Dondi E, Gardano L, Katzav S, Guittat L, Varin-Blank N. Oncotarget. 2015 Feb 10;6(4):2524-37.

Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previouslyuntreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. Dupuis J, Morschhauser F, Ghesquières H, Tilly H, Casasnovas O, Thieblemont C, Ribrag V, Bossard C, LeBras F, Bachy E, Hivert B, Nicolas-Virelizier E, Jardin F, Bastie JN, Amorim S, Lazarovici J, Martin A, Coiffier B. Lancet Haematol. 2015 Apr;2(4):e160-5.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P. Leuk Res. 2014 Jul;38(7):751-5.

High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer. Aparicio T, Schischmanoff O, Poupardin C, Mary F, Soufir N, Barrat C, Bellaiche G, Boubaya M, ChoudatL, Cucherousset J, DesGuetz G, Wind P, Benamouzig R. J Geriatr Oncol. 2014 Oct 1;5(4):384-8.

Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: highcorrelation with mRNA levels. Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, Martin A, Fabiani B, Delarue R, Tournilhac O, Delorenzi M, Gaulard P, de Leval L. Blood. 2014 Nov 6;124(19):2983-6.

High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer. Aparicio T, Schischmanoff O, Poupardin C, Mary F, Soufir N, Barrat C, Bellaiche G, Boubaya M, ChoudatL, Cucherousset J, DesGuetz G, Wind P, Benamouzig R. J Geriatr Oncol. 2014 Oct 1;5(4):384-8.

Munc18-2 and syntaxin 3 control distinct essential steps in mast cell degranulation. Brochetta C, Suzuki R, Vita F, Soranzo MR, Claver J, Madjene LC, Attout T, Vitte J, Varin-Blank N,Zabucchi G, Rivera J, Blank U. J Immunol. 2014 Jan 1;192(1):41-51.

Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia. Boudry-Labis E, Roche-Lestienne C, Nibourel O, Boissel N, Terre C, Perot C, Eclache V, Gachard N, Tigaud I, Plessis G, Cuccuini W, Geffroy S, Villenet C, Figeac M, Leprêtre F, Renneville A, Cheok M, Soulier J, Dombret H, Preudhomme C; French ALFA group. Am J Hematol. 2013 Apr;88(4):306-11.

Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients. Aparicio T, Schischmanoff O, Poupardin C, Soufir N, Angelakov C, Barrat C, Levy V, Choudat L, Cucherousset J, Boubaya M, Lagorce C, Guetz GD, Wind P, Benamouzig R. Dig Liver Dis. 2013 Mar;45(3):245-50.

Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia. Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Andrieux J, Eclache V, Bilhou-Nabera C, Luquet I, Terre C, Baranger L, Mugneret F, Chiesa J, Mozziconacci MJ, Callet-Bauchu E, Veronese L, Blons H, Owen R, Lejeune J, Chevret S, Merle-Beral H, Leblondon V; Groupe Français d'Etude de la Leucémie Lymphoïde Chronique et Maladie de Waldenström (GFCLL/MW); Groupe Ouest-Est d’étude des Leucémie Aiguës et Autres Maladies du Sang (GOELAMS); Groupe d’Etude des Lymphomes de l’Adulte (GELA). Haematologica. 2013 Apr;98(4):649-54.

Stillbirth classification in population-based data and role of fetal growth restriction: the example of RECODE. Ego A, Zeitlin J, Batailler P, Cornec S, Fondeur A, Baran-Marszak M, Jouk PS, Debillon T, Cans C. BMC Pregnancy Childbirth. 2013 Oct 3;13:182.

Acetazolamide and chronic hypoxia: effects on haemorheology and pulmonary haemodynamics. Pichon A, Connes P, Quidu P, Marchant D, Brunet J, Levy BI, Vilar J, Safeukui I, Cymbalista F, Maignan M,Richalet JP, Favret F. Eur Respir J. 2012 Dec;40(6):1401-9.

Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Sebaa A, Ades L, Baran-Marzack F, Mozziconacci MJ, Penther D, Dobbelstein S, Stamatoullas A, Récher C, Prebet T, Moulessehoul S, Fenaux P, Eclache V. Genes Chromosomes Cancer. 2012 Dec;51(12):1086-92.

Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? Cherry AM, Slovak ML, Campbell LJ, Chun K, Eclache V, Haase D, Haferlach C, Hildebrandt B, Iqbal AM, Jhanwar SC, Ohyashiki K, Sole F, Vandenberghe P, VanDyke DL, Zhang Y, Dewald GW. Leuk Res. 2012 Jul;36(7):832-40.

Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Put N, Van Roosbroeck K, Konings P, Meeus P, Brusselmans C, Rack K, Gervais C, Nguyen-Khac F, Chapiro E, Radford-Weiss I, Struski S, Dastugue N, Gachard N, Lefebvre C, Barin C, Eclache V, Fert-Ferrer S, Laibe S, Mozziconacci MJ, Quilichini B, Poirel HA, Wlodarska I, Hagemeijer A, Moreau Y, Vandenberghe P, Michaux L; BCGHo and the GFCH. Ann Hematol. 2012 Jun;91(6):863-73.

The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia. Le Roy C, Deglesne PA, Chevallier N, Beitar T, Eclache V, Quettier M, Boubaya M, Letestu R, Lévy V, Ajchenbaum-Cymbalista F, Varin-Blank N. Blood. 2012 Jul 12;120(2):356-65.

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumabin previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Blood. 2012 May 31;119(22):5104-10.

Catalase polymorphisms and metabolic diseases. Hebert-Schuster M, Fabre EE, Nivet-Antoine V. Curr Opin Clin Nutr Metab Care. 2012 Jul;15(4):397-402.